Porfiromycin
drugOn this page
Also known as N-methylmitomycin cNSC-56410PorfiromicinaPorfiromycineU-14,743U-14743SID26732566SID105809
Summary
Porfiromycin (CHEMBL521078) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including upper aerodigestive tract neoplasm and head and neck cancer.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 4
- Chemistry: 348.35 Da · C16H20N4O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL521078 |
| Name | Porfiromycin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 13116 |
| Molecular formula | C16H20N4O5 |
| Molecular weight | 348.35 |
| InChIKey | HRHKSTOGXBBQCB-VFWICMBZSA-N |
SMILES: CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4C)N
IUPAC name: [(4S,6S,7R,8S)-11-amino-7-methoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
Also known as: N-methylmitomycin c, NSC-56410, Porfiromicina, Porfiromycin, Porfiromycine, U-14,743, U-14743, SID26732566, SID105809, PORFIROMYCIN
Patent coverage: 6,023 distinct patent families (23,775 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Fructose-bisphosphate aldolase, Menin/Histone-lysine N-methyltransferase MLL.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| MAPT | 5.9 | Potency | 1259 | nM | CHEMBL_ACT_3962389 |
| MEN1 | 5.15 | Potency | 7080 | nM | CHEMBL_ACT_3620721 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| upper aerodigestive tract neoplasm | 3 | MONDO:0005398 | EFO:0004284 |
| head and neck cancer | 3 | MONDO:0005627 | EFO:0006859 |
| carcinoma | 3 | MONDO:0004993 | EFO:0000313 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00002507 | PHASE3 | COMPLETED | Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer |
| NCT00003328 | PHASE3 | COMPLETED | Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
| NCT02183246 | PHASE3 | TERMINATED | Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients |
| NCT02209701 | PHASE1 | TERMINATED | Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).